NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 912.9 DKK | -0.46% |
|
+3.36% | +30.77% |
| May. 16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
| May. 16 | Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 289B 42.17B | Sales 2025 * | 349B 50.87B | Capitalization | 4,067B 592B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.2B | Net income 2025 * | 127B 18.45B | EV / Sales 2024 * | 14.1 x |
| Net Debt 2024 * | 13.34B 1.94B | Net cash position 2025 * | 12.63B 1.84B | EV / Sales 2025 * | 11.6 x |
| P/E ratio 2024 * |
39.3
x | P/E ratio 2025 * |
32.2
x | Employees | 66,015 |
| Yield 2024 * |
1.29% | Yield 2025 * |
1.56% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More press releases
| 1 day | -0.46% | ||
| 1 week | +3.36% | ||
| Current month | +1.14% | ||
| 1 month | +3.83% | ||
| 3 months | +7.59% | ||
| 6 months | +35.45% | ||
| Current year | +30.77% |
1 week
883.20
927.00
1 month
826.70927.00
Current year
688.80932.00
1 year
504.40932.00
3 years
237.73932.00
5 years
155.30932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.52% | ||
| 10.45% | 5 M€ | +14.70% | ||
| 5.40% | 17 M€ | +7.35% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 912.9 | -0.46% | 3,350,700 |
| 24-05-15 | 917.1 | +0.78% | 2,120,311 |
| 24-05-14 | 910 | +0.01% | 3,118,148 |
| 24-05-13 | 909.9 | +3.02% | 4,150,455 |
| 24-05-08 | 883.2 | +0.07% | 2,737,492 |
Delayed Quote Nasdaq Copenhagen, May 16, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.77% | 595B | |
| +32.36% | 709B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B | |
| +0.45% | 163B |
- Stock Market
- Equities
- NOVO B Stock
